Swiss Rockets acquires Complete Genomics

Swiss Rockets AG, a Switzerland-based life sciences group, has agreed to acquire Complete Genomics, a U.S. company known for its next-generation DNA sequencing technology. The acquisition, subject to approval from shareholders of MGI, Complete Genomics' parent company, and customary closing conditions, will see Swiss Rockets taking full ownership and control of the U.S. firm. Specific financial terms have not been disclosed.

Post-acquisition, Swiss Rockets plans to leverage Complete Genomics' capabilities to reinforce its focus on targeted cancer therapies and next-generation vaccines. The acquisition aims to enhance Complete Genomics’ capacity for innovation and diversify its manufacturing capabilities. Dr. Vladimir Cmiljanovic, Swiss Rockets' CEO, will take over as CEO of Complete Genomics following the transaction's closure, while the existing U.S.-based management team will remain in charge of operations and product development.

The acquisition aligns with Swiss Rockets' strategy to expand its reach in precision medicine. By integrating Complete Genomics’ advanced sequencing platforms, Swiss Rockets hopes to bolster its development of new therapies and diagnostic tools. This strategic move is expected to enhance Complete Genomics’ technological portfolio, improve its supply chain, and accelerate its impact in genomics research globally. The company’s extensive record of over 10,900 supported scientific publications underscores its potential to contribute significantly to the combined entity.

The deal is significant within the life sciences sector, as Swiss Rockets seeks to fortify its market position through the acquisition of Complete Genomics' established sequencing solutions. As the life sciences industry places greater emphasis on cost-effective and flexible sequencing technologies, this acquisition positions Swiss Rockets to potentially lead in this competitive landscape by offering enhanced product offerings and maintaining continuity for Complete Genomics’ existing customer base.

Looking ahead, the focus will be on securing regulatory approvals and shareholder consent to finalize the transaction. The integration process will likely involve aligning the strategic goals of both companies, with further management appointments anticipated. The industry will monitor how effectively Swiss Rockets can capitalize on Complete Genomics’ existing infrastructure and intellectual property in its pursuit of innovation within personalized medicine.